Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been the object of insider selling activity recently. CLO Kamil Ali-jackson sold 3,738 shares at an average price of $20.35 on Fri the 26th. Ali-jackson now owns $412,881 of stock per an SEC filing yesterday.
Here are some other firms who have updated their holdings. As of quarter end Schwab Charles Investment Management Inc had bought 7,158 shares growing its holdings by 43.2%. The value of the investment in ACRS decreased from $447,000 to $439,000 decreasing 1.8% since the last quarter. Rock Springs Capital Management Lp expanded its ownership by buying 104,500 shares an increase of 11.7%. Rock Springs Capital Management Lp owns 1,000,000 shares worth $18,470,000. The total value of its holdings increased 8.8%.
As of the end of the quarter Cormorant Asset Management, LLC had acquired a total of 253,342 shares growing its position 39.1%. The value of the investment in Aclaris Therapeutics, Inc. went from $12,279,000 to $16,647,000 a change of $4,368,000 quarter to quarter. Manufacturers Life Insurance Company, The grew its position by buying 1,980 shares an increase of 83.7% from 03/31/2016 to 06/30/2016. Manufacturers Life Insurance Company, The claims 4,347 shares with a value of $80,000. The value of the position overall is up by 116.2%.
September 19 investment analysts at Jefferies left the company rating at “Buy” and raised the price expectation from $23.00 to $31.00. On August 12 Jefferies kept the stock rating at “Buy” but moved up the price target to $23.00 from $20.00.
On June 10 analysts at Guggenheim Securities starting coverage on ACRS with an initial rating of “Buy”. On March 16 Citigroup left the stock rating at “Buy” but lowered the price expectation to $29.00 from $34.00.
Jefferies issued its first research report on the stock by announcing an initial rating of “Buy” and setting a price target of $20.00. Equity analyst William Blair initiated coverage setting a rating of “Outperform” and a price target of $30.00.
The company is trading up since yesterday’s close of $25.15. Shares are trading at $25.29 a bit higher than the 50 day moving average which is $21.91 and which is a tad above the 200 day moving average of $19.97. The 50 day moving average was up $3.38 whereas the 200 day moving average was up $5.32 or +26.63%.
As of the last earnings report the EPS was $-2.79 and is estimated to be $-2.61 for the current year with 21,415,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.68 and the next full year EPS is projected to be $-2.81.
Traders are more bearish on shares of Aclaris Therapeutics, Inc. of late if you evaluate the increase in short interest. The company saw a rise in short interest of 0.04% between August 31, 2016 and September 15, 2016. Short interest increased from 622,175 to 646,086 over that period. The days to cover decreased to 0.0 and the percentage of shorted shares was 0.03% on September 15.